- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Base analog.
Displaying page 1 of 1.
EudraCT Number: 2016-004792-50 | Sponsor Protocol Number: C1502 | Start Date*: 2017-08-22 |
Sponsor Name:Biologische Heilmittel Heel GmbH | ||
Full Title: Multi-centre, Double-blind, Randomised, Active- and Placebo-Controlled, Confirmatory Trial to Demonstrate Efficacy and Safety of Traumed® Gel in Patients having Acute Ankle Sprain | ||
Medical condition: Acute Ankle Sprain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004899-30 | Sponsor Protocol Number: 111187 | Start Date*: 2016-12-21 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd. | ||
Full Title: Multi-center, Randomised, Double-blind, Parallel, Placebo Controlled Study Of 0.05% Clobetasone Butyrate Cream in Subjects with Eczema to evaluate the Efficacy and Safety. | ||
Medical condition: Eczema | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-001340-29 | Sponsor Protocol Number: IIBSP-LEV-2011-21 | Start Date*: 2011-09-16 |
Sponsor Name:Institut de Recerca del Hospital de la Santa Creu i Sant Pau | ||
Full Title: Effectiveness of Added blocking of radial and median nerves with levobupivacaine in the control of postoperative pain in the rhizarthrosis ambulatory surgery | ||
Medical condition: Rhizarthrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020953-14 | Sponsor Protocol Number: PosaBupreversion1.0 | Start Date*: 2010-08-12 |
Sponsor Name:Derartment of Anaesthesiology and Intensive Care, Turku University Hospital | ||
Full Title: Effects of posaconazole and voriconazole on the pharmacokinetics and pharmacodynamics of sublingual buprenorphine: A three-phase double-blind cross-over study in healthy subjects. | ||
Medical condition: - healty volunteer subjects - The study is aimed to examine the possible interactions of low-dose sublingual buprenorphine with posaconazole and voriconazole. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003816-38 | Sponsor Protocol Number: PHRC-N/2017-FJ-01 | Start Date*: 2020-11-09 | |||||||||||
Sponsor Name:CHU DE NIMES | |||||||||||||
Full Title: Add-on buprenorphine at analgesic doses for the treatment of severe suicidal ideas during a major depressive episode | |||||||||||||
Medical condition: Treatment of severe suicidal ideas in patients suffers from a current major depressive episode | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000250-22 | Sponsor Protocol Number: CVAY736X2201 | Start Date*: 2014-04-11 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A single dose, double-blind, placebo-controlled, parallel study to assess the pharmacodynamics, pharmacokinetics and safety and tolerability of VAY736 in patients with primary Sjögren’s syndrome | |||||||||||||
Medical condition: Seropositive primary Sjögren’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003927-45 | Sponsor Protocol Number: SENS-111-201 | Start Date*: 2017-05-04 | |||||||||||
Sponsor Name:Sensorion SA | |||||||||||||
Full Title: A multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patie... | |||||||||||||
Medical condition: Acute Unilateral Vestibulopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) HU (Completed) ES (Prematurely Ended) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003460-47 | Sponsor Protocol Number: LX1606.1-301-CS | Start Date*: 2012-12-19 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome N... | |||||||||||||
Medical condition: refractory carcinoid syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) IT (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002155-25 | Sponsor Protocol Number: TAK-448-2001 | Start Date*: 2014-11-17 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd | |||||||||||||
Full Title: An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism | |||||||||||||
Medical condition: Hypogonadotropic Hypogonadism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005712-22 | Sponsor Protocol Number: 01-2020 | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:Gedeon Richter Ibérica | |||||||||||||
Full Title: Prospective, randomized, multicenter study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and / or... | |||||||||||||
Medical condition: Osteoporosis in postmenopausal women at increased risk of fracture. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004271-37 | Sponsor Protocol Number: E7389-G000-204 | Start Date*: 2006-01-20 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemother... | |||||||||||||
Medical condition: Advanced/metastatic hormone-refractory prostate cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004524-11 | Sponsor Protocol Number: 2013105 | Start Date*: 2013-12-16 | ||||||||||||||||
Sponsor Name:Proctor and Gamble Technical Centres Ltd | ||||||||||||||||||
Full Title: A 2-arm, randomised, single - (investigator) blind, controlled, parallel design study in common cold sufferers experiencing cough and nasal congestion to assess the effects of Vicks® VapoRub® (VVR)... | ||||||||||||||||||
Medical condition: Sleep disruption due to cough and nasal congestion during a cold. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003330-32 | Sponsor Protocol Number: OSCO-P2201 | Start Date*: 2019-07-19 | |||||||||||
Sponsor Name:Oscotec Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite ... | |||||||||||||
Medical condition: Rheumatoid Arthritis Despite Treatment With Conventional Therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001543-31 | Sponsor Protocol Number: LX1606.1-303-CS | Start Date*: 2014-02-17 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome | |||||||||||||
Medical condition: Carcinoid Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) SE (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005209-23 | Sponsor Protocol Number: CA163139 | Start Date*: 2008-03-21 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/... | |||||||||||||
Medical condition: BREAST CANCER, FIRST LINE | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001457-26 | Sponsor Protocol Number: A6171016 | Start Date*: 2008-04-24 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTE... | |||||||||||||
Medical condition: Osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016720-31 | Sponsor Protocol Number: 250901 | Start Date*: 2010-06-09 | |||||||||||
Sponsor Name:Baxter Innovations GmbH [...] | |||||||||||||
Full Title: BAX 326 (recombinant Factor IX): A Phase 1/3 Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, Immunogenicity in Previously Treated Patients with Severe (FIX... | |||||||||||||
Medical condition: Previously treated patients with severe (FIX level < 1%) or moderately severe (FIX level ≤ 2%) hemophilia B. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009836-54 | Sponsor Protocol Number: CC-5013-CLL-009 | Start Date*: 2009-11-20 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF THE SAFETY AND EFFICACY OF DIFFERENT LENALIDOMIDE (REVLIMID®) DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL... | |||||||||||||
Medical condition: For the treatment of patients with B-cell chronic lymphocytic leukemia who have failed at least 1 prior therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) SE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018383-16 | Sponsor Protocol Number: C33457/2047 | Start Date*: 2010-09-17 | |||||||||||
Sponsor Name:Cephalon, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Patients With Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) ES (Completed) CZ (Completed) PT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
